The State of Molecular Biomarkers for the Early Detection of Lung Cancer

Overview

Journal Cancer Prev Res (Phila)

Specialty Oncology

Date 2012 Jun 13

PMID 22689914

Citations 109

Authors

Mohamed Hassanein

J Clay Callison

Carol Callaway-Lane

Melinda C Aldrich

Eric L Grogan

Pierre P Massion

Affiliations

Soon will be listed here.

Abstract

Using biomarkers to select the most at-risk population, to detect the disease while measurable and yet not clinically apparent has been the goal of many investigations. Recent advances in molecular strategies and analytic platforms, including genomics, epigenomics, proteomics, and metabolomics, have identified increasing numbers of potential biomarkers in the blood, urine, exhaled breath condensate, bronchial specimens, saliva, and sputum, but none have yet moved to the clinical setting. Therefore, there is a recognized gap between the promise and the product delivery in the cancer biomarker field. In this review, we define clinical contexts where risk and diagnostic biomarkers may have use in the management of lung cancer, identify the most relevant candidate biomarkers of early detection, provide their state of development, and finally discuss critical aspects of study design in molecular biomarkers for early detection of lung cancer.

Citing Articles

Multi-omics model is an effective means to diagnose benign and malignant pulmonary nodules.

Zhang Y, Zhang F, Shen C, Qiao G, Wang C, Jin F Clinics (Sao Paulo). 2025; 80:100599.

PMID: 39985828 PMC: 11904511. DOI: 10.1016/j.clinsp.2025.100599.

LncRNA MANCR is downregulated in non-small cell lung cancer and predicts poor survival.

Tao Y, Liu J, Qiu W, Li Y Discov Oncol. 2025; 16(1):40.

PMID: 39806185 PMC: 11730023. DOI: 10.1007/s12672-025-01739-5.

Telomere-based risk models for the early diagnosis of lung cancer.

Molina-Pinelo S, Ferrer Sanchez I, Najarro P, Paz-Ares L, Fernandez L, Castello N Heliyon. 2025; 10(24):e41040.

PMID: 39759351 PMC: 11696659. DOI: 10.1016/j.heliyon.2024.e41040.

Nanoparticle trends and hotspots in lung cancer diagnosis from 2006-2023: a bibliometric analysis.

Yilun W, Yaojing Z, Hongcan S Front Oncol. 2025; 14:1453021.

PMID: 39759141 PMC: 11695240. DOI: 10.3389/fonc.2024.1453021.

Periodontal Molecular Diagnostics: State of Knowledge and Future Prospects for Clinical Application.

Dolinska E, Wisniewski P, Pietruska M Int J Mol Sci. 2024; 25(23).

PMID: 39684335 PMC: 11641260. DOI: 10.3390/ijms252312624.

References

Halling K, Rickman O, Kipp B, Harwood A, Doerr C, Jett J . A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest. 2006; 130(3):694-701. DOI: 10.1378/chest.130.3.694. View

Chapman C, Murray A, McElveen J, Sahin U, Luxemburger U, Tureci O . Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax. 2007; 63(3):228-33. DOI: 10.1136/thx.2007.083592. View

Belinsky S, Palmisano W, Gilliland F, Crooks L, Divine K, Winters S . Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002; 62(8):2370-7. View

Janes H, Pepe M . Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value. Biometrics. 2007; 64(1):1-9. DOI: 10.1111/j.1541-0420.2007.00823.x. View

Pachmann K, Heiss P, Demel U, Tilz G . Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC). Clin Chem Lab Med. 2001; 39(9):811-7. DOI: 10.1515/CCLM.2001.134. View

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Bianchi F, Nicassio F, Marzi M, Belloni E, DallOlio V, Bernard L . A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011; 3(8):495-503. PMC: 3377091. DOI: 10.1002/emmm.201100154. View

Richards K, Zhang B, Sun M, Dong W, Churchill J, Bachinski L . Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. Cancer. 2010; 117(3):606-17. PMC: 3023841. DOI: 10.1002/cncr.25472. View

Isbell J, Deppen S, Putnam Jr J, Nesbitt J, Lambright E, Dawes A . Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation. Ann Thorac Surg. 2010; 91(1):227-33. PMC: 3748597. DOI: 10.1016/j.athoracsur.2010.08.054. View

10.

Lai C, Yu S, Hsieh M, Chen C, Chen H, Wen C . MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One. 2011; 6(6):e21635. PMC: 3126851. DOI: 10.1371/journal.pone.0021635. View

11.

Taguchi A, Politi K, Pitteri S, Lockwood W, Faca V, Kelly-Spratt K . Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 2011; 20(3):289-99. PMC: 3406925. DOI: 10.1016/j.ccr.2011.08.007. View

12.

Cummings S, Lillington G, Richard R . Estimating the probability of malignancy in solitary pulmonary nodules. A Bayesian approach. Am Rev Respir Dis. 1986; 134(3):449-52. DOI: 10.1164/arrd.1986.134.3.449. View

13.

Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S . Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009; 15(22):6980-6. DOI: 10.1158/1078-0432.CCR-09-1095. View

14.

Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T . A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst. 2007; 99(11):858-67. DOI: 10.1093/jnci/djk197. View

15.

Mazzone P . Analysis of volatile organic compounds in the exhaled breath for the diagnosis of lung cancer. J Thorac Oncol. 2008; 3(7):774-80. DOI: 10.1097/JTO.0b013e31817c7439. View

16.

Kneip C, Schmidt B, Seegebarth A, Weickmann S, Fleischhacker M, Liebenberg V . SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol. 2011; 6(10):1632-8. DOI: 10.1097/JTO.0b013e318220ef9a. View

17.

Anglim P, Galler J, Koss M, Hagen J, Turla S, Campan M . Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer. 2008; 7:62. PMC: 2483990. DOI: 10.1186/1476-4598-7-62. View

18.

Yildiz P, Shyr Y, Rahman J, Wardwell N, Zimmerman L, Shakhtour B . Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol. 2007; 2(10):893-901. PMC: 4220686. DOI: 10.1097/JTO.0b013e31814b8be7. View

19.

Feng Q, Hawes S, Stern J, Wiens L, Lu H, Dong Z . DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2008; 17(3):645-54. PMC: 2798850. DOI: 10.1158/1055-9965.EPI-07-2518. View

20.

Showe M, Vachani A, Kossenkov A, Yousef M, Nichols C, Nikonova E . Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res. 2009; 69(24):9202-10. PMC: 2798582. DOI: 10.1158/0008-5472.CAN-09-1378. View